Clinical Trial

An Immunity Persistence Study of Live Attenuated Varicella Vaccine

Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Summary
This an open phase Ⅳ clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunity persistence of live attenuated varicella vaccine at 5 and 8 years after primary immunization with live attenuated varicella vaccine.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-10-14; most recent amendment 2025-01-23.
Status change: Not Yet Recruiting → Enrolling by Invitation 2024-03-06
Trial Details
NCT Number NCT05095701
Lead Sponsor Sinovac (Dalian) Vaccine Technology Co., Ltd.
Conditions Varicella
Enrollment 703 participants
Start Date 2021-12-18
Primary Completion 2021-12-19 (estimated)
Study Completion 2025-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-27